Discontinued — last reported Q4 '17
Non-Current Assets
Intangibles (Net)
Gilead Sciences Intangibles (Net) increased by 528.8% to $16.98B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.9%, from $19.95B to $16.98B. Over 5 years (FY 2020 to FY 2025), Intangibles (Net) shows a downward trend with a -12.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryMarket Position
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2017
How to read this metric
High levels reflect significant investment in growth through acquisitions; changes indicate the impact of amortization or impairment charges.
Detailed definition
This includes the value of acquired intellectual property, such as patents, trademarks, and drug licenses, net of accumu...
Peer comparison
Very high in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.
Metric ID:
intangible_assets_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.22B | $17.78B | $33.46B | $17.11B | $16.67B | $16.22B | $28.89B | $21.23B | $20.63B | $20.03B | $26.45B | $4.64B | $4.64B | $2.89B | $19.95B | $2.89B | $2.70B | $2.70B | $16.98B |
| QoQ Change | — | -2.4% | +88.2% | -48.9% | -2.6% | -2.7% | +78.1% | -26.5% | -2.8% | -2.9% | +32.1% | -82.5% | +0.0% | -37.7% | +590.2% | -85.5% | -6.6% | +0.0% | +528.8% |
| YoY Change | — | — | — | — | -8.5% | -8.8% | -13.6% | +24.1% | +23.8% | +23.5% | -8.4% | -78.1% | -77.5% | -85.6% | -24.6% | -37.7% | -41.8% | -6.6% | -14.9% |
Range$2.70B – $33.46B
CAGR-1.6%
Avg YoY Growth-22.3%
Median YoY Growth-13.6%
Current Streak2 quarters growth
Intangibles (Net) at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's intangibles (net)?
- Gilead Sciences (GILD) reported intangibles (net) of $16.98B in Q4 2025.
- How has Gilead Sciences's intangibles (net) changed year-over-year?
- Gilead Sciences's intangibles (net) decreased by 14.9% year-over-year, from $19.95B to $16.98B.
- What is the long-term trend for Gilead Sciences's intangibles (net)?
- Over 5 years (2020 to 2025), Gilead Sciences's intangibles (net) has grown at a -12.5% compound annual growth rate (CAGR), from $33.13B to $16.98B.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and brand names, minus their amortized cost.